Dare Bioscience (DARE) vs Phio Pharmaceuticals (PHIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Phio Pharmaceuticals (PHIO) has outperformed Dare Bioscience (DARE) over the past year, losing 41.4% versus a loss of 75.8%. Over five years, DARE leads with a -98.1% price change compared with -99.6% for PHIO. Dare Bioscience is the larger company by market cap ($8.0 million vs $7.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DARE | PHIO |
|---|---|---|
| Share price | $0.4074 | $0.656 |
| Market cap | $8.01M | $7.84M |
| 1-day change | -9.87% | -8.25% |
| YTD return | -78.89% | -37.52% |
| 1-year return | -75.75% | -41.43% |
| 5-year return | -98.10% | -99.56% |
| EPS (TTM) | $-0.61 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.03M | — |
| Revenue growth (YoY) | +10429.36% | — |
| Net income (latest FY) | $-13.40M | $-8.70M |
| Gross margin | 71.29% | — |
| Operating margin | -1315.51% | — |
| Net margin | -1300.66% | — |
| 52-week high | $3.78 | $1.88 |
| 52-week low | $0.406 | $0.6395 |
| Distance from 52-week high | -89.22% | -65.11% |
| Analyst consensus | none | none |
| Avg. price target upside | +1944.67% | +2034.15% |
| Average volume | 242.39K | 106.09K |
| Shares outstanding | 19.67M | 11.95M |
| Employees | 21 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHIO has outperformed DARE by 34.3 percentage points over the past year.
About Dare Bioscience
DARE stock →Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Phio Pharmaceuticals
PHIO stock →Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
DARE vs PHIO FAQ
Which is bigger, Dare Bioscience or Phio Pharmaceuticals?
Dare Bioscience (DARE) is larger, with a market capitalization of $8.01M compared with $7.84M for Phio Pharmaceuticals (PHIO).
Which stock has performed better over the past year, DARE or PHIO?
PHIO returned -41.43% over the past 12 months, compared with -75.75% for DARE (price return, excluding dividends). Past performance does not predict future results.
Are Dare Bioscience and Phio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.